HKSTP
23.9.2020 14:26:12 CEST | Business Wire | Press release
Hong Kong Science and Technology Parks Corporation (HKSTP) announced that the Elevator Pitch Competition 2020 (EPiC 2020) is now inviting applications from around the world. Given current global circumstances, HKSTP will stage the event on a virtual platform for the first time. Local and international startups and innovators can go beyond the geographic boundaries and unlock tremendous opportunities at EPiC 2020, which will take place from 6 to 13 November.
Marking its fifth anniversary, EPiC 2020 comprises a series of one-week events for the 150 contestants shortlisted from a competitive pool of global-wide applications. The startups will simulate the signature 60-second elevator ride to pitch their innovative business ideas virtually via a 1-minute video to a judging panel of major investors and industry leaders, who will select the top 10 finalists. The finalists will be announced during the final pitching competition on 6 November where they will battle to be named EPiC champion of 2020 in a 5-minute presentation plus a Q&A session.
Following the Pitching Competition, the contestants also have the chance to explore cross-border business and investment opportunities to help propel their technology innovation across all key stages of the entrepreneurial journey. The Global Matching Day programme, which will happen from 9 to 12 November, connects the best startups with thousands of leading investors and corporate leaders to explore business opportunities in the Greater Bay Area and Asia Pacific. The “Investment x Corporate Innovation Conference” on 13 November concludes the EPiC week by bringing together I&T heavyweights and global pioneers to discuss the regional investment opportunities and share the ways to drive corporate innovation and growth.
Albert Wong, CEO of HKSTP, said, “EPiC 2020, as our annual flagship event, is a unique platform to connect international innovation and technology (I&T) talent, startups and investors to accelerate global partnerships and collaborations. We are hosting our first-ever virtual EPiC this year to drive greater value and synergies among entrepreneurs and corporates across the globe in view of market challenges.”
“At HKSTP, our belief in entrepreneurial spirit and our commitment to sustaining the growth of the I&T ecosystem remain as strong as ever. We strive to provide a beacon of growth opportunity for startups around the world and support them across the critical early stages of their innovation journey.”
Last year, the competition attracted a record number of 650 entries from 48 countries and cities across the globe. Over 70% of the finalists were from 33 different overseas markets, including Australia, Canada, India, Japan, New Zealand, Singapore and the United States, among others. The event brought more than 1,000 entrepreneurs, venture capital firms, angel investors, industry players, incubators, accelerators and tech disruptors together, to sustain the I&T ecosystem in Hong Kong.
Who can apply:
- Tech startups that are less than five years old and have received less than US$10 million in funding by 31 March 2020 OR individuals who have not yet established any companies
- Ideas should focus on one of the four technology areas: Artificial Intelligence & Robotics, FinTech, Health Technology and Smart City.
Applications will close on 19 October 2020, at 23:59 hrs, Hong Kong time.
Please visit https://epic.hkstp.org/ for more detailed information on EPiC 2020.
List of awards and prizes
Award |
Cash Prize
|
Champion |
US$100,000 |
4 Tech Winners
|
US$10,000 |
Top 10 Finalists |
US$6,000 |
# # #
About Hong Kong Science and Technology Parks Corporation
Comprising Science Park, InnoCentre and Industrial Estates, Hong Kong Science & Technology Parks Corporation (HKSTP) is a statutory body dedicated to building a vibrant innovation and technology ecosystem to connect stakeholders, nurture technology talents, facilitate collaboration, and catalyse innovations to deliver social and economic benefits to Hong Kong and the region.
Established in May 2001, HKSTP has been driving the development of Hong Kong into a regional hub for innovation and growth in several focused clusters including Electronics, Information & Communications Technology, Green Technology, Biomedical Technology, Materials and Precision Engineering. We enable science and technology companies to nurture ideas, innovate and grow, supported by our R&D facilities, infrastructure, and market-led laboratories and technical centres with professional support services. We also offer value added services and comprehensive incubation programmes for technology start-ups to accelerate their growth.
Technology businesses benefit from our specialised services and infrastructure at Science Park for applied research and product development; enterprises can find creative design support at InnoCentre; while skill-intensive businesses are served by our three industrial estates at Tai Po, Tseung Kwan O and Yuen Long. More information about HKSTP is available at www.hkstp.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200923005526/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom